Wall Street Is Finally Noticing Small Caps

JPMorgan announced this week that it is building a new investment banking team dedicated entirely to small-cap dealmaking, targeting companies valued between $100 million and $500 million. The team will sit alongside the bank’s existing middle-market group, which covers companies between $500 million and $1 billion and already employs nearly 400 bankers. According to an internal memo reported by Yahoo Finance, the new group will be based in New York, Los Angeles, Dallas, Chicago, and Atlanta, with plans to hire more than 75 bankers in the near term. It will start by focusing on diversified industries, consumer and retail, and business services, led by new hire Michael Flynn, a veteran middle-market banker.

It is a notable move for a bank of JPMorgan’s size. But for investors who have been paying attention to small and micro caps all year, this is a confirmation, not a discovery.

The Russell 2000 gained nearly 22% in the first half of 2026, its best first-half performance since 1991, outpacing the S&P 500 and Dow’s roughly 9% gains and the Nasdaq’s 13% rise. Every sector in the index finished the first half in positive territory, led by technology, industrials, financials, and healthcare. Analysts have pointed to easing financial conditions, a healthier credit backdrop, and valuations that remain meaningfully discounted relative to large caps as reasons the rally has legs. Small caps also tend to benefit disproportionately once a rate-cutting cycle takes hold, since a larger share of their balance sheets rely on variable or shorter-term financing.

What JPMorgan’s move really signals is that the largest pools of capital are starting to reposition toward a part of the market that has been overlooked for the better part of a decade. Big banks do not build out dedicated coverage teams on a whim. They do it when deal flow, IPO activity, and client demand justify the headcount, and that kind of infrastructure typically follows smart money into a space rather than leading it there.

That kind of institutional attention tends to arrive with real consequences for pricing. More bankers covering the space usually means more IPOs, more M&A activity, more equity research, and ultimately more liquidity flowing into names that have traded at a discount simply because fewer people were watching them closely. Small caps have historically underperformed for years at a time before snapping back sharply once capital rotates in, and that rotation is often driven by exactly this kind of institutional repositioning rather than a single catalyst.

For investors, the takeaway is straightforward. Institutional capital chasing small caps tends to compress the valuation gap that made the space attractive in the first place. Getting positioned ahead of that convergence, rather than after it, is where the real opportunity sits. With small caps already outperforming and now drawing this kind of attention from a bank the size of JPMorgan, the window to act on that discount looks like it will not stay open indefinitely.

MAIA Biotechnology (MAIA) – First Data From Phase 2 Part C Trial Shows Data Consistent With Earlier Studies


Thursday, July 09, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Data From Part C Announced. MAIA announced data from Part C (Expansion stage) of its Phase 2 THIO-101 trial in non-small cell lung cancer (NSCLC). This open-label stage of the trial tests the combination of ateganosine and cemiplimab (Libtayo, from Regeneron) as a third-line (3L) therapy for patients with advanced disease that no longer respond to other therapies. The data after the first evaluation have a Disease Control Rate (DCR) of 90.5% (19 out of 21 patients), compared with published rates of 25% to 35%. We view this as a good sign that patient responses are consistent with previous data.

Design Of the Phase 2 THIO-101 Trial. The Phase 2 THIO-101 Expansion stage is the third part of the Phase 2 trial. Part A tested safety, while Part B was for dose optimization and selection. Part C is currently testing the combination of the 180 mg dose of ateganosine with cemiplimab. If positive, the data could be used to apply for accelerated approval from the FDA.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

AZZ (AZZ) – First Quarter FY27 Financial Results Exceed Expectations; Guidance Raised


Thursday, July 09, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

FY 2027 First Quarter Financial Results. AZZ reported adjusted net income of $55.8 million, or $1.85 per share, compared to $53.8 million, or $1.78 per share, during the prior year period. We had forecast adjusted net income of $51.4 million or $1.70 per share. Compared to the first quarter of FY 2026, sales increased 6.3% to $448.5 million. Adjusted EBITDA amounted to $99.5 million compared to our estimate of $96.8 million. Compared to the prior year period, first quarter Metal Coatings sales were up 12.3% to $210.3 million, while Precoat Metal sales increased 1.5% to $238.2 million. First quarter segment adjusted EBITDA margin amounted to 30.3% for Metal Coatings and 21.7% for Precoat Metals.

FY 2027 Corporate Guidance. Management now expects FY 2027 sales in the range of $1.80 to $1.85 billion, compared to previous expectations of $1.725 to $1.775 billion. Adjusted EBITDA is expected to be in the range of $375 to $415 million, compared to prior guidance of $360 to $400 million. Adjusted EPS is now projected to be $6.75 to $7.15 versus prior expectations of $6.50 to $7.00.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Why the Fed’s July Meeting Matters More for Small Caps Than Anyone Else

The Russell 2000 has gained 33.8% over the past twelve months, comfortably beating the S&P 500’s 20% return, and just posted its best first-half performance since 1991. That’s the headline every small-cap investor has been celebrating. The number underneath it tells a different story.

Interest expense now consumes 31% of EBITDA for companies in the Russell 2000, the heaviest debt-servicing burden these companies have carried in at least six years. Nearly 30% of small-cap corporate debt sits on floating rates, meaning it resets with whatever the Federal Reserve does next rather than staying locked in at yesterday’s borrowing costs. By comparison, floating-rate debt makes up only about 7% of S&P 500 balance sheets, and large-cap interest expense sits at just 6.7% of EBITDA. Small caps have always carried more leverage relative to earnings than their large-cap counterparts. What’s changed is how expensive that leverage has become to service, and how much more exposed small caps are to the Fed’s next move than the rest of the market.

The mechanics here matter more for small caps than almost anywhere else in the market. Large-cap companies tend to term out their debt for years at fixed rates and carry investment-grade credit ratings that keep borrowing costs manageable even when the Fed holds rates higher for longer. Small caps don’t have that luxury. They borrow shorter, they borrow at higher spreads to begin with, and a much larger share of that borrowing floats with prevailing rates. When the Fed moves, small-cap balance sheets feel it first and feel it hardest.

That’s exactly why this rally has been happening in a market environment that should, in theory, be working against it. The Fed under Chair Kevin Warsh has taken a notably hawkish posture this year, and traders have spent recent months pricing in the possibility of an actual rate increase rather than the cuts most investors expected heading into 2026. Small caps have rallied anyway, which tells you the earnings growth story has been strong enough to outrun the rate pressure so far.

The risk is what happens if that earnings momentum slows while rates stay elevated or move higher. A company with debt priced at a wide spread over a floating benchmark doesn’t get relief just because its revenue is growing. If margins compress at all, from wage inflation, input costs, or slowing demand, the interest bill doesn’t shrink to match. It’s the same amount of debt service pulled from a smaller pool of operating income, and at 31% of EBITDA already, there isn’t a lot of room to absorb a shock before it starts showing up in earnings per share. Nearly 40% of Russell 2000 companies are already unprofitable, which leaves a meaningful chunk of the index with even less cushion.

The Fed’s next meeting lands July 28-29, and it’s arguably a more important date for small-cap investors than for the broader market. A hold or a dovish tone gives the current rally room to keep running. A hike, or even language that keeps a hike on the table for the fall, tightens the exact pressure point that’s already the most fragile part of the small-cap balance sheet. For anyone riding this year’s small-cap strength, the momentum is real, but so is the leverage sitting underneath it.

Chemomab and Scipher Merge to Bring AI-Guided Precision Medicine to Rheumatoid Arthritis

Two small-cap biotechs are betting that artificial intelligence can succeed where a decade of drug development has stalled. Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine announced this morning that they have entered into a definitive merger agreement, combining Chemomab’s clinical-stage antibody nebokitug with Scipher’s AI-powered precision medicine platform to attack rheumatoid arthritis from a completely different angle than anything currently on the market.

The numbers explain why this matters. No new mechanism of action has been approved for rheumatoid arthritis since 2012, and no new branded therapy has reached the market since 2019. Only about a third of RA patients achieve low disease activity on current treatments, and the two leading drug classes now carry FDA boxed warnings. It’s a $24 billion market that has effectively been standing still for over a decade while patients cycle through drugs that only partially work.

Chemomab’s contribution is nebokitug, a first-in-class antibody that blocks CCL24, a protein tied to both inflammation and fibrosis. That dual mechanism is the differentiator. Most RA drugs on the market today only address inflammation, leaving the fibrotic, tissue-scarring side of the disease untouched. Nebokitug has already produced positive results across five clinical trials, including a Phase 2 study in primary sclerosing cholangitis that hit its safety endpoint and improved a range of fibrosis-related markers.

Scipher brings the half of the equation that makes this deal genuinely interesting. The company’s AI Network Medicine platform independently ranked CCL24 as the top therapeutic target for RA, arriving at the same conclusion Chemomab had reached through years of bench research, but from a completely different direction. Scipher also owns PrismRA, the only rheumatoid arthritis test with Medicare and Medicaid reimbursement approval for predicting how a patient will respond to treatment. That test will be used to select patients for the upcoming Phase 2 trial, meaning the study isn’t just testing whether nebokitug works. It’s testing whether AI-selected patients respond better than an unselected population, which is precisely the kind of precision-medicine proof point regulators and physicians have been waiting for.

Under the deal terms, the combined company will operate as Scipher Medicine Corporation and trade under the ticker SCIP. Scipher shareholders will hold roughly 68% of the combined entity, with Chemomab shareholders holding about 32% plus contingent value rights tied to nebokitug milestones. A syndicate led by Northpond Ventures, with Khosla Ventures, Blue Owl Healthcare Opportunities, and Neuberger funds participating, is putting in $30 million to fund the combined company. That capital, together with existing cash, is expected to carry operations into the second half of 2028, well past the Phase 2 readout expected in the first half of that year.

The deal values the combined company at $150 million before the new financing, a modest figure for a company sitting on a potential first-in-market precision medicine therapy for a disease affecting more than 20 million people worldwide. Scipher also brings existing revenue through biopharma partnerships and its immunology data business, giving the combined company more than one path to funding its pipeline while the RA trial plays out.

The transaction still needs shareholder approval from both companies and an SEC-cleared S-4 registration statement, with closing targeted for the fourth quarter of 2026.

Commercial Vehicle Group (CVGI) – First Raise Under Capital on Demand Agreement


Wednesday, July 08, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

First Raise. Commercial Vehicle Group reported that it has made the first raise under the recently announced $25 million Capital on Demand agreement. As of June 29, 2026, the Company had sold 2.6 million shares of common stock in the ATM Program, generating net proceeds of approximately $11.6 million.

Use of Proceeds. As required by the Company’s secured term loan facility, all net proceeds were used by the Company to pay down outstanding indebtedness and the associated prepayment premium under the facility. As we noted previously, as of June 17, 2026, outstanding indebtedness under the Term Loan was $80 million. The Term Loan matures in June 2030 with a current interest rate of 13.47%. Any reduction in the outstanding loan balance is a positive for the Company, in our view, not only reducing high-cost debt but also eventually providing additional financial flexibility.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

FreightCar America (RAIL) – Strong Order Activity Reinforces Outlook


Wednesday, July 08, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Commercial momentum. FreightCar America secured a multi-year order for 1,900 railcars from a key customer, with deliveries scheduled through 2028. Combined with approximately 3,000 railcars ordered during the second quarter valued at roughly $300 million, the multi-year order highlights strong commercial demand and improves long-term backlog visibility.

Broad Customer Demand. Second quarter orders were received across all core market segments and included both new and existing customers, demonstrating the company’s expanding commercial reach and diversified product portfolio. The order activity reflects growing confidence in RAIL’s engineering expertise, manufacturing flexibility, and ability to execute reliably.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The Real AI Trade Nobody’s Talking About: Why Data Center Cooling Just Became a Billion-Dollar Business

Ecolab just paid $4.75 billion in cash for a Calgary-based company most investors have never heard of, and that single transaction tells you more about where AI infrastructure spending is headed than almost anything happening in chips right now.

The March 2026 acquisition of CoolIT Systems came at a price of 29 times next-twelve-months adjusted EBITDA. That is not the kind of multiple a serious industrial buyer pays on a whim. It’s a signal that liquid cooling has moved from a nice-to-have into a required piece of the AI data center stack, and Ecolab is not the only one who has figured that out.

The math behind the move is simple physics more than anything else. Modern AI training runs on GPU servers packed with far more processing density than traditional data centers were ever built to handle, and that density generates heat that conventional air cooling simply cannot dissipate fast enough. Nvidia’s newest Blackwell racks push thermal loads that force operators into direct-to-chip cooling, rear-door heat exchangers, or full immersion systems just to keep the hardware running. ASHRAE’s 2026 AI Data Center Energy Performance Framework now names these approaches explicitly as requirements, not options, for high-density AI deployments. MarketsandMarkets pegs the global liquid cooling market at $4.07 billion this year, growing to $27.65 billion by 2033, a 31.5% annual growth rate that would make most industries jealous.

Ecolab’s purchase of CoolIT is just the most recent entry in a run of consolidation that has been building for over a year. Trane Technologies has announced plans to acquire LiquidStack. Schneider Electric bought Motivair in 2025 specifically to build out its liquid cooling capabilities. Vertiv closed its acquisition of ThermoKey on June 12 and opened a new manufacturing facility in Malaysia on July 1 just to keep up with AI infrastructure orders. Every major player in industrial thermal management has either bought a specialist in this space or announced plans to. When that many strategic acquirers are willing to pay near 30 times forward earnings for private cooling companies, the public small and micro-cap names sitting in the same value chain tend to get repriced whether or not they’re involved in a deal themselves.

A handful of small-cap names sit right in the middle of this shift. Modine Manufacturing has spent the last three years transforming itself from a legacy automotive parts supplier into a company focused on data center thermal management, divesting older auto businesses along the way to sharpen that story. Limbach Holdings has leaned into the build-out from a different angle, highlighting its modular construction and prefabrication platform for data centers in a June announcement that positions the company squarely inside the high-density projects hyperscalers are commissioning right now. And nVent Electric, which has spent more than a decade building liquid cooling distribution and high-density power systems, saw organic orders jump roughly 65% in a recent quarter driven almost entirely by large cooling orders tied to hyperscaler programs. The company has already deployed more than a gigawatt of cooling capacity across its installed base.

The AI investment story so far has mostly been about chips, and understandably so. But chips are useless if you can’t keep them cool enough to run at full capacity, and that second half of the equation is where the next wave of investment dollars appears to be heading. Power, water, and industrial thermal management are becoming just as important to the AI buildout as the silicon itself, and the M&A activity happening right now is the clearest evidence yet that the biggest names in industrial equipment already see it that way. Modine, Limbach, and nVent aren’t household names, and that’s exactly the point. When a $77 billion company pays nearly $5 billion for a private cooling specialist, the small-cap names doing similar work for the same customers are the ones worth watching next.

Michael Burry Bets Against Micron After Its Best Quarter Ever. Is the AI Memory Boom About to Bust?

Michael Burry just shorted one of the best-performing stocks in the market, and the reasoning behind it is worth understanding whether you own semiconductor stocks or not.

The Scion Asset Management founder disclosed a new short position in Micron Technology (NASDAQ: MU) in a Substack post on July 2, entering at $1,051.87 per share. The stock dropped roughly 5.5% on the news, closing at $975.56. Burry also holds existing short positions in Nvidia, Applied Materials, and the iShares Semiconductor ETF (SOXX), and has said publicly that AI-related chip stocks could see a 30% correction from here.

Burry’s argument centers on one word: cyclicality. “Micron defines cyclical like no other,” he wrote, and he backed it up with numbers that are hard to wave away. The stock has suffered 34 drawdowns of more than 30% over the past 42 years. Its median return on invested capital sits at just 4%. Median return on equity comes in at 7%, which Burry called “frankly terrible.” Free cash flow has gone negative in 48% of quarters historically. And right now, Micron is trading further above its 200-day moving average than at any point since 1984, a stretch that includes the dot-com bubble. Burry dismissed the high-bandwidth memory business fueling the current rally as “just another in a very long series” of Micron products rather than a durable competitive edge.

It’s a compelling case built on four decades of history. The problem is that Micron’s most recent quarter does not look like the start of a downturn. For the period ending May 2026, the company posted $41.5 billion in revenue, up 345.7% year over year, with gross margin expanding to 84.6% from 37.7% a year earlier. On the June 24 earnings call, Chief Business Officer Sumit Sadana said customer demand for memory chips remains “well above our ability to supply” across nearly every product category through 2028. Long-term supply contracts, some running five years with prepayments attached, now account for at least half of the company’s revenue. That is not the profile of a business quietly cracking under the weight of a boom-and-bust cycle. It looks like a company locking in demand years in advance.

So which read is right? The piece of Burry’s argument that deserves the most attention isn’t the historical volatility data, it’s what he pointed to as the actual catalyst. South Korea recently announced mega semiconductor projects worth at least 1.35 trillion won, roughly $880 billion, including new fabrication plants from Samsung and SK Hynix. Burry called this “the beginning of the end.” Samsung, SK Hynix, and Micron together control close to 90% of the global DRAM market. When two of the three dominant players start committing hundreds of billions of dollars to new capacity, the pricing power that has driven this year’s memory rally typically doesn’t last forever. Supply eventually catches up to demand, and when it does in this industry, it tends to overshoot.

That dynamic is becoming more real by the day. SK Hynix debuted its U.S. listing today, raising approximately $28 billion in fresh capital, much of which is aimed squarely at expanding memory production capacity. Meanwhile, insiders at Micron have sold $124.9 million worth of shares over the past three months, a detail that doesn’t prove anything on its own but is worth filing away.

None of this settles the debate, and it shouldn’t. Micron is not a small or micro-cap company, but the memory supply chain it sits atop runs through dozens of smaller public names in testing, packaging, specialty materials, and thermal management, all of which trade on the same underlying cycle. When one of the most recognizable short sellers in the market publicly challenges the sustainability of an AI-driven supercycle in the exact stock that anchors that supply chain, the ripple effects extend well past Micron’s own share price. Investors holding exposure anywhere in the memory ecosystem now have a credible bear case sitting alongside the bull case, and the coming quarters, particularly how HBM pricing holds up against the wave of new South Korean capacity, will likely determine who was right.

CoreCivic, Inc. (CXW) – Validation of Asset Worth


Tuesday, July 07, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Asset Sale. CoreCivic sold two detention facilities— the 2,560-bed California City Detention Facility in California City, California, and the 1,994-bed Otay Mesa Detention Facility in San Diego-to the U.S. Government for gross proceeds of $1.5 billion or approximately $1.1 billion in net proceeds. Significantly, CoreCivic expects to continue to manage both facilities under existing management contracts with ICE.

Value Validation. Cal City sold for $286,172 per bed and Otay Mesa for $370,712 per bed. Even acknowledging a “California premium,” the facilities sold significantly above previous sales of detention facilities on a per-bed basis, confirming our long-standing thesis that the Company’s assets are worth well in excess of what the market is giving the Company credit for.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Microsoft Just Torched 3,200 Xbox Jobs and Admitted the Console Model Is Broken

Microsoft (NASDAQ: MSFT) announced this morning that it is cutting 4,800 roles across the company, roughly 2.1% of its workforce. The bulk of the pain, 3,200 positions, lands in the Xbox division. The stock fell more than 1% on the news. Microsoft is now down about 20% year to date, while Alphabet is up 14% and Amazon is up 5%.

But the layoff count is not the story. The story is what Xbox CEO Asha Sharma actually wrote in her memo to employees.

The Quote That Should Get Every Console Investor’s Attention

“Our business today is not healthy,” Sharma told her team. “We are operating at margins that are 3-10x lower than comparable platform and publishing businesses. We must reset XBOX.” She followed it with an even sharper number. “In a typical year, we lost 64 cents for every dollar we invested.”

That is a public admission from a Big Tech executive that an entire business unit has been burning cash at a structural rate. It is unusually blunt, and it is worth paying attention to.

What Is Actually Happening

The first round of cuts includes 1,600 employees today. Microsoft is moving four studios, Ninja Theory, Undead Labs, Compulsion Games, and Double Fine Productions, to outside management. It is working to sell or spin off a fifth, Arkane Studios in France. Sharma also flagged that some workflows pass through 14 layers of management, which she plans to compress to no more than five and ideally three.

Sharma took over Xbox in February and has already cut the price of Game Pass and reworked branding. This move is her most aggressive yet.

The context matters. Microsoft entered this console generation with a smaller install base and higher costs than Sony and Nintendo. The company then poured money into putting first-party games on rival platforms and expanding Game Pass, and the payoff never materialized. Meanwhile, the entire industry is facing a memory and storage crisis that has forced Microsoft, Sony, and Nintendo to raise console prices. Nintendo shares are down 52% over the past twelve months. Sony is off 17%.

The AI Overhang

Microsoft chief people officer Amy Coleman said none of the eliminated roles will be replaced by AI, but acknowledged the technology is changing how work gets done. That is corporate-speak for a much larger issue investors have been chewing on all year. Microsoft is spending heavily on AI infrastructure while the market is questioning whether AI labs will eventually displace demand for Microsoft 365 and its productivity stack. When your legacy cash cow is under pressure and your legacy loss-maker is being amputated on the same day, the market notices.

Why Small and Micro-Cap Investors Should Care

This is not just a Microsoft story. Console economics have propped up a range of small and micro-cap suppliers, developers, and specialty publishers for decades. A serious restructuring at Xbox has downstream implications for independent studios, middleware providers, gaming peripheral makers, and cloud gaming infrastructure names. The four studios moving to outside management, plus Arkane looking for a home, could create acquisition opportunities or standalone independence stories worth tracking.

There is also a broader read-through for anyone holding legacy technology names. When a business as embedded as Xbox can be publicly declared unhealthy by its own leadership, it forces investors to ask which other legacy businesses are quietly burning capital while management waits for the right moment to act.

The Bottom Line

Microsoft is not in trouble. It is a $3 trillion company that just made a hard call on a division that has been dragging on margins for years. But when a Big Tech leader tells you the console model is losing 64 cents on every dollar, believe her. The consumer technology stack is being repriced in real time, and the small caps that live downstream from it are next in line for the same conversation.

Ondas Just Made an $876 Million Bet on Autonomous Defense

Ondas Inc. (NASDAQ: ONDS) went from a small-cap autonomous systems name to a serious player in the defense technology conversation this morning. The company announced it has closed on the acquisition of DZYNE Technologies for $875.8 million, a deal that reshapes the company’s revenue base, its product portfolio, and arguably its entire investment thesis.

The transaction was funded through a mix of cash and stock. DZYNE shareholders received $200 million in cash and roughly 85 million Ondas shares valued at approximately $675 million. That leaves the DZYNE group, led by private equity firm Highlander Partners, holding about 13.8% of Ondas’ outstanding shares. More than half of the equity consideration, 45 million shares, is subject to a six-month lock-up. That is a meaningful signal about how the sellers view the combined company.

What Ondas Just Bought

DZYNE is a U.S. defense technology company known for long-endurance autonomous aircraft, counter-drone systems, and what the industry now calls “autonomous effects.” Translated, that means expendable, low-cost unmanned platforms designed to be deployed at scale rather than treated as high-value single assets. The Pentagon has been pushing this “affordable mass” concept aggressively, and DZYNE sits directly in the middle of it.

The DZYNE portfolio brings three distinct franchises to Ondas. ULTRA is a long-endurance ISR aircraft with tens of thousands of operational flight hours already logged. IonStrike is a kinetic counter-drone interceptor purpose-built to defeat Shahed-136 class attack drones, the kind that have become a defining threat in modern conflict. Blitz is a Group 1 UAS with 150 kilometers of range and swarm capabilities. Grasshopper is an autonomous cargo glider that delivers up to 500 pounds into contested environments. Add Dronebuster, one of the most widely fielded handheld counter-drone systems in the world, and Ondas now owns a portfolio that has absorbed more than $500 million in cumulative R&D.

The Financial Case

This is where the story gets interesting for small-cap investors. DZYNE is expected to generate $191 million in revenue for 2026 and more than $300 million in 2027. The company is already EBITDA positive with margins targeted in the mid-teens for 2027 and the mid-20% range by 2028.

Ondas raised its 2026 revenue target to at least $525 million, up meaningfully from the prior target of at least $390 million. That figure includes DZYNE and the Omnisys acquisition that closed in May, but does not yet include Cyberhawk, which is expected to close in the third quarter. The company is guiding to a greater than 80% revenue CAGR from 2025 through 2028.

Ondas Sentinel

To manage the expanding U.S. defense portfolio, Ondas is forming a new operating division called Ondas Sentinel. It will house DZYNE alongside World View, the stratospheric platform business Ondas already owned. Ryan Hartman, currently CEO of World View, will run Ondas Sentinel as CEO. Matt McCue, co-founder and CEO of DZYNE, becomes CTO. The structure gives Ondas an integrated ISR stack that spans stratospheric sensing, long-endurance theater ISR, and tactical-edge autonomous operations, all connected through SkyWeaver, a mission software layer being built on Palantir Foundry and AIP.

The Bottom Line

Small-cap defense has been one of the most active corners of the market this year, and Ondas just planted a flag. The company is now positioned as a serious platform play in autonomous defense, with real revenue, positive EBITDA contribution, and a product suite aligned to the exact priorities the Department of War is funding. Execution risk on integration is real, and the share issuance is meaningful dilution. But the pro forma company Ondas described this morning looks very different from the one investors owned last week.

Take a moment and take a look at other small cap defense companies like Kratos Defense & Security Solutions and V2X.

NanoViricides (NNVC) – Novel Technology With Broad-Spectrum Antiviral Applications In Development


Monday, July 06, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

We Are Initiating Coverage With An Outperform Rating. NanoViricides has a proprietary technology platform that it has used to formulate antivirals with a unique mechanism of action. These drugs, called nanoviricides, have been designed to carry a peptide sequence that the virus recognizes as a binding site on a host cell, effectively acting as decoys that the virus binds to instead of healthy cells. Once bound to the drug, the virus is trapped and neutralized.

NV-387 Addresses Viral Outbreaks and Pandemic Preparedness. The lead product, NV-387, is in development for MPox, Ebola, and smallpox. A Phase 2a trial evaluating NV-387 for treating MPox in the Democratic Republic of Congo (DRC) is expected to begin treatment in mid-2027, followed by a Phase 2a in Ebola. Initial data is expected to be available toward the end of 2027.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.